MBX Biosciences, Inc. Share Price
MBXMBX Biosciences, Inc. Stock Performance
Open $54.40 | Prev. Close $53.93 | Circuit Range N/A |
Day Range $53.91 - $57.36 | Year Range $9.64 - $57.36 | Volume 1,08,623 |
Average Traded $55.92 |
MBX Biosciences, Inc. Share Price Chart
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Jun-26 | $54.40 | $55.18 | +0.00% |
30-Jun-26 | $54.40 | $55.18 | +2.47% |
29-Jun-26 | $52.12 | $53.85 | +3.08% |
26-Jun-26 | $49.95 | $52.24 | +3.62% |
25-Jun-26 | $48.55 | $50.41 | +4.20% |
24-Jun-26 | $46.00 | $48.38 | +3.94% |
23-Jun-26 | $43.01 | $46.55 | +6.25% |